PT - JOURNAL ARTICLE AU - Hamidouche, Mohamed TI - COVID-19 outbreak in Algeria: A mathematical Model to predict cumulative cases AID - 10.1101/2020.03.20.20039891 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.20.20039891 4099 - http://medrxiv.org/content/early/2020/03/27/2020.03.20.20039891.short 4100 - http://medrxiv.org/content/early/2020/03/27/2020.03.20.20039891.full AB - Introduction Since December 29, 2019 a pandemic of new novel coronavirus-infected pneumonia named COVID-19 has started from Wuhan, China, has led to 254 996 confirmed cases until midday March 20, 2020. Sporadic cases have been imported worldwide, in Algeria, the first case reported on February 25, 2020 was imported from Italy, and then the epidemic has spread to other parts of the country very quickly with 139 confirmed cases until March 21, 2020.Methods It is crucial to estimate the cases number growth in the early stages of the outbreak, to this end, we have implemented the Alg-COVID-19 Model which allows to predict the incidence and the reproduction number R0 in the coming months in order to help decision makers.The Alg-COVIS-19 Model initial equation 1, estimates the cumulative cases at t prediction time using two parameters: the reproduction number R0 and the serial interval SI.Results We found R0=2.55 based on actual incidence at the first 25 days, using the serial interval SI= 4,4 and the prediction time t=26. The herd immunity HI estimated is HI=61%. Also, The Covid-19 incidence predicted with the Alg-COVID-19 Model fits closely the actual incidence during the first 26 days of the epidemic in Algeria Fig. 1.A. which allows us to use it.According to Alg-COVID-19 Model, the number of cases will exceed 5000 on the 42th day (April 7th) and it will double to 10000 on 46th day of the epidemic (April 11th), thus, exponential phase will begin (Table 1; Fig.1.B) and increases continuously until reaching à herd immunity of 61% unless serious preventive measures are considered.Discussion This model is valid only when the majority of the population is vulnerable to COVID-19 infection, however, it can be updated to fit the new parameters values.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding has been providedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data refferd to in the manuscript is available